Loteprednol information

Loteprednol
Clinical data
Trade names	Lotemax
Other names	11β,17α,Dihydroxy-21-oxa-21-chloromethylpregna-1,4-diene-3,20-dione 17α-ethylcarbonate
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of; administration	Eye drops
Drug class	Corticosteroid; glucocorticoid
ATC code	S01BA14 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	None
Protein binding	95%
Metabolism	Ester hydrolysis
Metabolites	Δ1-cortienic acid and its etabonate
Onset of action	≤2 hrs (allergic conjunctivitis)
Elimination half-life	2.8 hrs
Identifiers
	IUPAC name Chloromethyl 17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate;
CAS Number	82034-46-6 ;
PubChem CID	444025;
IUPHAR/BPS	7085;
DrugBank	DB14596 ;
ChemSpider	392049 ;
UNII	YEH1EZ96K6;
KEGG	D01689 ;
ChEBI	CHEBI:31784 ;
ChEMBL	ChEMBL1200865 ;
CompTox Dashboard (EPA)	DTXSID2046468 ;
ECHA InfoCard	100.167.120
Chemical and physical data
Formula	C24H31ClO7
Molar mass	466.96 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	220.5 to 223.5 °C (428.9 to 434.3 °F)
Solubility in water	0.0005 mg/mL (20 °C)
	SMILES CCOC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)OCCl;
	InChI InChI=1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h7,9,11,16-19,27H,4-6,8,10,12-13H2,1-3H3/t16-,17-,18-,19+,22-,23-,24-/m0/s1 ; Key:DMKSVUSAATWOCU-HROMYWEYSA-N ;
	(what is this?) (verify)

Loteprednol (synthesized as the ester loteprednol etabonate) is a topical corticosteroid used to treat inflammations of the eye. It is marketed by Bausch and Lomb as Lotemax^[2] and Loterex.

It was patented in 1980 and approved for medical use in 1998.^[3] It is available as a generic medication.^[4]

^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^ Cite error: The named reference AC was invoked but never defined (see the help page).
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 488. ISBN 9783527607495.
^ "First Generic Drug Approvals 2023". U.S. Food and Drug Administration (FDA). 30 May 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.

[1] "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

[AC-2] Cite error: The named reference AC was invoked but never defined (see the help page).

[Fis2006-3] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 488. ISBN 9783527607495.

[4] "First Generic Drug Approvals 2023". U.S. Food and Drug Administration (FDA). 30 May 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.

Loteprednol information

and 26 Related for: Loteprednol information

Loteprednol

Phlyctenular keratoconjunctivitis

ATC code S01

Cortisol

Progesterone

Glucocorticoid

Betamethasone valerate

Corticosteroid

Triamcinolone acetonide

Fluticasone

Prednisone

Methylprednisolone

Fluocinonide

Hydrocortisone

Triamcinolone

Clobetasol

Clobetasol propionate

Fluticasone propionate

Ketoconazole

Betamethasone dipropionate

Trenbolone acetate

Cortisone

Deflazacort

Fluticasone furoate

Prednisolone

Allergic conjunctivitis